{"caseSensitive":true,"concept":[{"code":"PEGylated","definition":"Conjugated to one or more polyethylene glycol (PEG) chains for half-life extension. Examples: pegfilgrastim, peginterferon, certolizumab pegol.","display":"PEGylated"},{"code":"lipidated","definition":"Conjugated to a fatty acid chain (acylation) for half-life extension via albumin binding. Examples: semaglutide, liraglutide, insulin detemir, insulin degludec.","display":"Lipidated"},{"code":"Fc-fused","definition":"Fused to an immunoglobulin Fc region for half-life extension and effector function. Examples: etanercept, abatacept, aflibercept, dulaglutide.","display":"Fc fusion"},{"code":"albumin-fused","definition":"Fused to human serum albumin for half-life extension. Example: albiglutide.","display":"Albumin fusion"},{"code":"drug-conjugated","definition":"Conjugated to a small-molecule drug payload via a linker (antibody-drug conjugate). Examples: trastuzumab emtansine, brentuximab vedotin, gemtuzumab ozogamicin.","display":"Drug-conjugated (ADC)"},{"code":"polysaccharide-conjugated","definition":"Conjugated to a polysaccharide antigen for vaccine immunogenicity. Examples: Hib, pneumococcal and meningococcal conjugate vaccines.","display":"Polysaccharide-conjugated"},{"code":"glycoengineered","definition":"Glycan structure engineered (e.g. afucosylated) to alter biological activity. Examples: obinutuzumab, mogamulizumab (enhanced ADCC).","display":"Glycoengineered"},{"code":"amino-acid-substituted","definition":"Sequence carries one or more amino acid substitutions relative to a natural or parent protein. Examples: insulin analogs lispro, aspart, glargine.","display":"Amino acid substituted"},{"code":"truncated","definition":"Sequence is shortened relative to the parent protein.","display":"Truncated"},{"code":"biotinylated","definition":"Covalently labelled with biotin. Typical for research or diagnostic reagents.","display":"Biotinylated"},{"code":"fluorescent-labeled","definition":"Covalently labelled with a fluorescent dye. Typical for imaging or flow-cytometry reagents.","display":"Fluorescent labelled"}],"contact":[{"telecom":[{"system":"url","value":"http://hl7.org/fhir"},{"system":"email","value":"fhir@lists.hl7.org"}]}],"content":"complete","date":"2026-06-30","description":"A high-level summary of how a protein has been modified, e.g. PEGylation, lipidation, Fc fusion. Useful for categorising modified biologics without enumerating the detailed chemistry.","experimental":true,"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"},{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status","valueCode":"informative"},{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm","valueInteger":1}],"id":"protein-modification-type","jurisdiction":[{"coding":[{"code":"001","display":"World","system":"http://unstats.un.org/unsd/methods/m49/m49.htm"}]}],"meta":{"lastUpdated":"2026-07-04T18:53:58.933+00:00"},"name":"ProteinModificationTypeExample","publisher":"HL7 (FHIR Project)","resourceType":"CodeSystem","status":"active","text":{"div":"

Generated Narrative: CodeSystem protein-modification-type

This case-sensitive code system http://hl7.org/fhir/protein-modification-type defines the following codes:

CodeDisplayDefinition
PEGylated PEGylatedConjugated to one or more polyethylene glycol (PEG) chains for half-life extension. Examples: pegfilgrastim, peginterferon, certolizumab pegol.
lipidated LipidatedConjugated to a fatty acid chain (acylation) for half-life extension via albumin binding. Examples: semaglutide, liraglutide, insulin detemir, insulin degludec.
Fc-fused Fc fusionFused to an immunoglobulin Fc region for half-life extension and effector function. Examples: etanercept, abatacept, aflibercept, dulaglutide.
albumin-fused Albumin fusionFused to human serum albumin for half-life extension. Example: albiglutide.
drug-conjugated Drug-conjugated (ADC)Conjugated to a small-molecule drug payload via a linker (antibody-drug conjugate). Examples: trastuzumab emtansine, brentuximab vedotin, gemtuzumab ozogamicin.
polysaccharide-conjugated Polysaccharide-conjugatedConjugated to a polysaccharide antigen for vaccine immunogenicity. Examples: Hib, pneumococcal and meningococcal conjugate vaccines.
glycoengineered GlycoengineeredGlycan structure engineered (e.g. afucosylated) to alter biological activity. Examples: obinutuzumab, mogamulizumab (enhanced ADCC).
amino-acid-substituted Amino acid substitutedSequence carries one or more amino acid substitutions relative to a natural or parent protein. Examples: insulin analogs lispro, aspart, glargine.
truncated TruncatedSequence is shortened relative to the parent protein.
biotinylated BiotinylatedCovalently labelled with biotin. Typical for research or diagnostic reagents.
fluorescent-labeled Fluorescent labelledCovalently labelled with a fluorescent dye. Typical for imaging or flow-cytometry reagents.
","status":"generated"},"title":"Protein Modification Type","url":"http://hl7.org/fhir/protein-modification-type","valueSet":"http://hl7.org/fhir/ValueSet/protein-modification-type","version":"6.0.0-ballot4"}